Complex respiratory portfolio propels Cipla towards profitability, says Sharekhan report

A report from brokerage firm Sharekhan highlighted key factors contributing to Cipla's upward trajectory, emphasizing the company's strategic focus on complex products and the resultant impact on margins.

Related Keywords

South Africa , ,Cipla ,Price Target ,Indian Pharmaceutical Market ,Moving Annual Total ,Earnings Before Interest ,Factor Pharma ,Earnings Per Share ,Uot Complex Respiratory Portfolio ,Ipla Profitability ,Harekhan Report ,Pharmaceutical Sector ,Ipla Growth Figures ,Arnings Before Interest Taxes Depreciation And Amortization Margins ,Strategic Initiatives ,Ctor Pharma Acquisition ,Ipla Financial Indicators ,Price To Earnings Ratio ,Market Growth Prospects ,S Market ,Hronic Products ,New Product Launches ,Price Erosion ,Therapeutic Segments ,Investment Opportunity ,Albuterol ,Rovana ,Anreotide Quot ,